Literature DB >> 12064785

Phonatory characteristics of parkinsonian speech before and after morning medication: the ON and OFF states.

Alexander Goberman1, Carl Coelho, Michael Robb.   

Abstract

UNLABELLED: After prolonged treatment with L-dopa, patients with Parkinson's disease (PD) experience fluctuations in motor performance. Changes in voice production have been documented perceptually during periods of fluctuation, but few quantitative changes have been found. The purpose of this study is to examine the acoustic-phonatory characteristics of PD speech before and after taking medication, to determine if fluctuations affected phonation. Nine PD patients participated in this study. Multiple analyses were performed, and revealed that fundamental frequency (Fo) variability in vowels and mean Fo were higher, while intensity range was lower in PD patients compared to controls. When the PD subjects were examined after versus before medication, group differences were small, but phonatory improvements were seen in individual subjects. Discussion focuses on physiological changes and variability in PD, and implications of response fluctuations to speech production. LEARNING OUTCOMES: As a result of this activity, the participant will be able to (1) acquire knowledge and understanding of PD and the voice characteristics commonly associated with PD and (2) understand the effects of L-dopa-related fluctuations on voice production in PD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12064785     DOI: 10.1016/s0021-9924(01)00072-7

Source DB:  PubMed          Journal:  J Commun Disord        ISSN: 0021-9924            Impact factor:   2.288


  25 in total

1.  Evaluation of speech impairment in early stages of Parkinson's disease: a prospective study with the role of pharmacotherapy.

Authors:  Jan Rusz; Roman Cmejla; Hana Růžičková; Jiří Klempíř; Veronika Majerová; Jana Picmausová; Jan Roth; Evžen Růžička
Journal:  J Neural Transm (Vienna)       Date:  2012-07-08       Impact factor: 3.575

2.  Effects of Parkinson's Disease on Fundamental Frequency Variability in Running Speech.

Authors:  Leah K Bowen; Gabrielle L Hands; Sujata Pradhan; Cara E Stepp
Journal:  J Med Speech Lang Pathol       Date:  2013-09

3.  Clear Speech Variants: An Acoustic Study in Parkinson's Disease.

Authors:  Jennifer Lam; Kris Tjaden
Journal:  J Speech Lang Hear Res       Date:  2016-08-01       Impact factor: 2.297

Review 4.  Behavioral and neurophysiological correlates of striatal dopamine depletion: a rodent model of Parkinson's disease.

Authors:  Emily K Plowman; Jeffrey A Kleim
Journal:  J Commun Disord       Date:  2011-04-30       Impact factor: 2.288

5.  Remote capture of human voice acoustical data by telephone: a methods study.

Authors:  Michael S Cannizzaro; Nicole Reilly; James C Mundt; Peter J Snyder
Journal:  Clin Linguist Phon       Date:  2005-12       Impact factor: 1.346

6.  Listener Perception of Monopitch, Naturalness, and Intelligibility for Speakers With Parkinson's Disease.

Authors:  Supraja Anand; Cara E Stepp
Journal:  J Speech Lang Hear Res       Date:  2015-08       Impact factor: 2.297

7.  Short- and long-term dopaminergic effects on dysarthria in early Parkinson's disease.

Authors:  Sabine Skodda; Wenke Visser; Uwe Schlegel
Journal:  J Neural Transm (Vienna)       Date:  2009-12-12       Impact factor: 3.575

8.  Measures to Evaluate the Effects of DBS on Speech Production.

Authors:  Gary Weismer; Yana Yunusova; Kate Bunton
Journal:  J Neurolinguistics       Date:  2012-03       Impact factor: 1.710

9.  Relative fundamental frequency during vocal onset and offset in older speakers with and without Parkinson's disease.

Authors:  Cara E Stepp
Journal:  J Acoust Soc Am       Date:  2013-03       Impact factor: 1.840

10.  Reduction of dopamine synaptic activity: degradation of 50-kHz ultrasonic vocalization in rats.

Authors:  Michelle R Ciucci; Allison M Ahrens; Sean T Ma; Jacqueline R Kane; E Blake Windham; Martin T Woodlee; Timothy Schallert
Journal:  Behav Neurosci       Date:  2009-04       Impact factor: 1.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.